Breaking News Instant updates and real-time market news.

SLDB

Solid Biosciences

$25.66

-2.95 (-10.31%)

06:35
12/10/18
12/10
06:35
12/10/18
06:35

Solid Biosciences initiated with a Neutral at BTIG

BTIG analyst Timothy Chiang initiated Solid Biosciences with a Neutral rating. The analyst notes that the company is one of three players with a micro-dystrophin gene therapy for the treatment of Duchenne Muscular Dystrophy, or DMD, but also does not expect that program to gain approval until 2022. Chiang further states that he anticipates the peak sales potential for gene therapies for DMD to take place in 2024-2025 and believes that the current valuation on Solid Biosciences reflects those expectations.

SLDB Solid Biosciences
$25.66

-2.95 (-10.31%)

12/03/18
SBSH
12/03/18
NO CHANGE
Target $31
SBSH
Sell
Solid Biosciences price target raised to $31 from $25 at Citi
Citi analyst Joel Beatty raised his price target for Solid Biosciences to $31 after the company successfully dosed two additional patients "without an additional clinical hold or a major safety event." The analyst, however, keeps a Sell rating on the shares. He continues to believe Solid will have to dose escalate twice more to reach a commercially competitive dose.
11/06/18
SBSH
11/06/18
INITIATION
Target $25
SBSH
Sell
Solid Biosciences initiated with a Sell at Citi
Citi analyst Joel Beatty started Solid Biosciences (SLDB) with a Sell rating and $25 price target. The analyst believes the gene therapy agents in clinical development for Duchenne muscular dystrophy by Sarepta (SRPT) and Pfizer (PFE) will leave little market share to Solid Bio's SGT-001. The analyst forecasts Sarepta capturing the largest share of the DMD gene therapy market, followed by Pfizer, and then Solid.
09/06/18
FBCO
09/06/18
INITIATION
Target $38
FBCO
Neutral
Solid Biosciences initiated with a Neutral at Credit Suisse
Credit Suisse analyst Martin Auster started Solid Biosciences with a Neutral rating and $38 price target. The analyst notes that the company's DMD gene therapy, SGT-001, has clear mechanistic rationale and is well supported by preclinical proof-of-concept. Auster anticipates clinical differentiation, time to market, and durability will be among the most meaningful arbiters of value among the three clinical stage DMD gene therapy products and expects longer term data to refine his thinking and modeling assumptions.
06/25/18
NOMU
06/25/18
NO CHANGE
Target $57
NOMU
Buy
Solid Biosciences price target raised to $57 from $37 at Nomura Instinet
Nomura Instinet analyst Christopher Marai raised his price target on Solid Biosciences (SLDB) to $57 from $37 after Sarepta (SRPT) presented key biopsy data showing biochemical success of the AAV/microdystrophin approach, which Solid is also investigating. Marai maintains his Buy rating on Solid Biosciences shares.

TODAY'S FREE FLY STORIES

WBA

Walgreens Boots Alliance

$62.35

0.09 (0.14%)

10:46
11/12/19
11/12
10:46
11/12/19
10:46
Recommendations
Walgreens Boots Alliance analyst commentary  »

Walgreens Boots could be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

  • 22

    Nov

QSR

Restaurant Brands

$67.39

-0.15 (-0.22%)

10:45
11/12/19
11/12
10:45
11/12/19
10:45
Options
Restaurant Brands call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:45
11/12/19
11/12
10:45
11/12/19
10:45
General news
Breaking General news story  »

4-Week Bill Announcement…

10:45
11/12/19
11/12
10:45
11/12/19
10:45
General news
Breaking General news story  »

8-Week Bill Announcement…

F

Ford

$9.11

0.03 (0.33%)

, GM

General Motors

$38.89

0.18 (0.46%)

10:38
11/12/19
11/12
10:38
11/12/19
10:38
Periodicals
Trump expected to extend deadline for EU car tariffs, Bloomberg says »

The Trump administration…

F

Ford

$9.11

0.03 (0.33%)

GM

General Motors

$38.89

0.18 (0.46%)

HMC

Honda

$29.35

0.15 (0.51%)

NSANY

Nissan

$0.00

(0.00%)

TM

Toyota

$145.00

-0.07 (-0.05%)

TSLA

Tesla

$348.78

3.71 (1.08%)

DDAIF

Daimler AG

$0.00

(0.00%)

FCAU

Fiat Chrysler

$16.21

0.1 (0.62%)

VWAGY

Volkswagen

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 09

    Dec

  • 04

    Feb

KSS

Kohl's

$56.48

-0.56 (-0.98%)

10:35
11/12/19
11/12
10:35
11/12/19
10:35
Options
Kohl's put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

10:35
11/12/19
11/12
10:35
11/12/19
10:35
General news
FX Action: USD-JPY »

FX Action: USD-JPY…

DIS

Disney

$139.04

2.3 (1.68%)

10:31
11/12/19
11/12
10:31
11/12/19
10:31
Hot Stocks
Disney says Disney+ 'exceeded our high expectations,' working on glitches »

Disney+ Help tweeted,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KHC

Kraft Heinz

$32.77

0.01 (0.03%)

10:25
11/12/19
11/12
10:25
11/12/19
10:25
Options
Kraft Heinz call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RHHBY

Roche

$0.00

(0.00%)

10:25
11/12/19
11/12
10:25
11/12/19
10:25
Conference/Events
Roche to hold a conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

  • 12

    Nov

  • 07

    Dec

REPL

Replimune Group

$17.24

0.11 (0.64%)

10:25
11/12/19
11/12
10:25
11/12/19
10:25
Conference/Events
Replimune Group participates in a conference call with JPMorgan »

SMid Biotech Analyst Rama…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

  • 12

    Nov

10:25
11/12/19
11/12
10:25
11/12/19
10:25
Conference/Events
UBS technology analysts to hold an analyst/industry conference call »

Technology Analysts…

LH

LabCorp

$165.45

-0.29 (-0.17%)

10:23
11/12/19
11/12
10:23
11/12/19
10:23
Syndicate
Breaking Syndicate news story on LabCorp »

LabCorp files automatic…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CRWD

Crowdstrike

$47.57

1.39 (3.01%)

, TEVA

Teva

$9.36

0.03 (0.32%)

10:21
11/12/19
11/12
10:21
11/12/19
10:21
On The Fly
JPMorgan gets less bearish on Xerox among today's top calls on Wall Street »

Check out today's top…

CRWD

Crowdstrike

$47.57

1.39 (3.01%)

TEVA

Teva

$9.36

0.03 (0.32%)

AMRX

Amneal Pharmaceuticals

$2.69

0.05 (1.89%)

XRX

Xerox

$38.05

-0.28 (-0.73%)

HPQ

HP Inc.

$19.33

-0.31 (-1.58%)

AMAT

Applied Materials

$56.81

0.21 (0.37%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

  • 20

    Nov

  • 26

    Nov

  • 05

    Dec

  • 07

    Dec

  • 09

    Dec

  • 09

    Dec

  • 12

    Dec

UCBJY

UCB

$0.00

(0.00%)

10:20
11/12/19
11/12
10:20
11/12/19
10:20
Conference/Events
UCB participates in a conference call with JPMorgan »

European Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMRN

Amarin

$19.92

3.02 (17.87%)

10:18
11/12/19
11/12
10:18
11/12/19
10:18
On The Fly
Analysts see good odds of Amarin's Vascepa label expansion after docs posted »

Stifel analyst Derek…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

  • 28

    Dec

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

10:17
11/12/19
11/12
10:17
11/12/19
10:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ARLO

Arlo Technologies

$2.84

0.18 (6.77%)

, CCC

Clarivate Analytics

$17.22

0.13 (0.76%)

10:16
11/12/19
11/12
10:16
11/12/19
10:16
Initiation
Fly Intel: Top five analyst initiations »

Catch up on today's…

ARLO

Arlo Technologies

$2.84

0.18 (6.77%)

CCC

Clarivate Analytics

$17.22

0.13 (0.76%)

STOK

Stoke Therapeutics

$30.87

1.04 (3.49%)

BMRN

BioMarin

$75.96

0.72 (0.96%)

BIIB

Biogen

$291.50

-2.41 (-0.82%)

AMGN

Amgen

$223.35

2.66 (1.21%)

CTVA

Corteva

$27.06

0.32 (1.20%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

  • 12

    Nov

  • 07

    Dec

  • 09

    Dec

CSX

CSX

$72.89

-1.04 (-1.41%)

, ETN

Eaton

$91.78

-0.09 (-0.10%)

10:16
11/12/19
11/12
10:16
11/12/19
10:16
Initiation
Fly Intel: Top five analyst downgrades »

Catch up on today's…

CSX

CSX

$72.89

-1.04 (-1.41%)

ETN

Eaton

$91.78

-0.09 (-0.10%)

AMRX

Amneal Pharmaceuticals

$2.71

0.07 (2.65%)

ALB

Albemarle

$67.47

-0.25 (-0.37%)

BOX

Box

$15.93

-0.52 (-3.16%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

  • 13

    Nov

  • 19

    Nov

  • 19

    Nov

  • 19

    Nov

  • 26

    Nov

  • 12

    Dec

ARGO

Argo Group

$63.82

2.54 (4.14%)

, LYV

Live Nation

$64.79

0.32 (0.50%)

10:16
11/12/19
11/12
10:16
11/12/19
10:16
Upgrade
Fly Intel: Top five analyst upgrades »

Catch up on today's…

ARGO

Argo Group

$63.82

2.54 (4.14%)

LYV

Live Nation

$64.79

0.32 (0.50%)

RCII

Rent-A-Center

$23.13

0.78 (3.49%)

CRWD

Crowdstrike

$47.25

1.07 (2.32%)

TEVA

Teva

$9.40

0.07 (0.75%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 07

    Dec

  • 12

    Dec

$NYE

NYSE Market Internals

$0.00

(0.00%)

10:16
11/12/19
11/12
10:16
11/12/19
10:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DIS

Disney

$138.17

1.43 (1.05%)

10:15
11/12/19
11/12
10:15
11/12/19
10:15
Periodicals
Disney tells CNBC streaming service launch exceeds 'high expectations' »

CNBC reported via Twitter…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

S

Sprint

$5.90

-0.01 (-0.17%)

10:15
11/12/19
11/12
10:15
11/12/19
10:15
Options
Sprint put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

IDRA

Idera Pharmaceuticals

$2.29

0.06 (2.69%)

10:15
11/12/19
11/12
10:15
11/12/19
10:15
Conference/Events
Idera Pharmaceuticals participates in a conference call with JPMorgan »

SMid Biotech Analyst Rama…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DIS

Disney

$138.25

1.51 (1.10%)

10:12
11/12/19
11/12
10:12
11/12/19
10:12
Periodicals
Disney working to fix Disney+ issues amid 'incredible response,' TechCrunch says »

Disney+ users have been…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.